# Formoterol in Diabetes

Study · id `cardio:ct-nct07022418` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07022418](<https://clinicaltrials.gov/study/NCT07022418>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07022418

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07022418. Randomized; no masking; primary purpose treatment. Start 2025-12-01 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07022418, source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)
- Started: 2025-12-01 (actual) (ClinicalTrials.gov record NCT07022418, source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07022418, source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07022418, source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07022418, source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07022418-2026-02-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Formoterol in Diabetes
- Condition: Diabetic Nephropathies
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Formoterol furmarate (20 μg)
- Lead sponsor: Medical University of South Carolina
- Lead sponsor class: OTHER
- Collaborator: Dialysis Clinic, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Medical University of South Carolina (`cardio:org-medical-university-of-south-carolina`)

## Provenance

Content hash: d1adcab8b19b1563809f84167e392a3bd39cefbc5aea8957df9d7de43f6e5140
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
